Acute Lymphoblastic Leukaemia Recurrent Recruiting Phase 2 Trials for Daunorubicin (DB00694)

Also known as: Acute lymphoblastic leukemia recurrent / Recurrent Acute lymphoblastic leukemia / Acute, recurrent Lymphoblastic Leukaemia / Relapsed ALL / Acute, recurrent Lymphoblastic Leukemia / Acute, relapsed Lymphoblastic Leukemia / Relapsed Acute Lymphoblastic Leukemia / Acute lymphocytic leukemia recurrent / Acute lymphocytic leukaemia recurrent

IndicationStatusPhase
DBCOND0083559 (Acute Lymphoblastic Leukaemia Recurrent)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03575325Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic LeukemiaTreatment